Payment overview · 2025
General Payments
$360.31
12 reported records · 10 companies
Healthcare provider profile · identity verified
Rajendra Prasad, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1427119536
Verified facts
What the public records show
CMS Open Payments records show Rajendra Prasad, M.D. received $360.31 in general payments during 2025 across 12 reported records.
ANI Pharmaceuticals, Inc. accounted for 32.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Kerendia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 541 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $116.99 | 32.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.65 | 10.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.58 | 9.3% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.31 | 8.1% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $29.04 | 8.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $28.73 | 8.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.88 | 6.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.39 | 5.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.22 | 5.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $19.52 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $360.31 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $116.99 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.65 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $33.58 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $29.31 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $29.04 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $28.73 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
541 | 49 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1158 | 198 |
| Amlodipine Besylate | Amlodipine Besylate | 962 | 187 |
| Gabapentin | Gabapentin | 706 | 124 |
| Eliquis | Apixaban | 541 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 489 | 85 |
| Furosemide | Furosemide | 472 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 433 | 97 |
| Lisinopril | Lisinopril | 399 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 395 | 68 |
| Metformin Hcl | Metformin Hcl | 376 | 85 |
| Carvedilol | Carvedilol | 364 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 334 | 58 |
| Levetiracetam | Levetiracetam | 290 | 39 |
| Famotidine | Famotidine | 273 | 55 |
| Hydralazine Hcl | Hydralazine Hcl | 273 | 68 |
| Losartan Potassium | Losartan Potassium | 262 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 241 | 38 |
| Ibuprofen | Ibuprofen | 221 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 217 | 52 |
| Quetiapine Fumarate | Quetiapine Fumarate | 216 | 34 |
| Clonidine Hcl | Clonidine Hcl | 208 | 62 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 208 | 49 |
| Omeprazole | Omeprazole | 206 | 48 |
| Mirtazapine | Mirtazapine | 204 | 46 |
| Meloxicam | Meloxicam | 200 | 42 |
| Risperidone | Risperidone | 180 | 27 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 171 | 40 |
| Divalproex Sodium | Divalproex Sodium | 169 | 22 |
| Finasteride | Finasteride | 159 | 28 |
| Potassium Chloride | Potassium Chloride | 154 | 28 |
| Jardiance | Empagliflozin | 151 | 23 |
| Trazodone Hcl | Trazodone Hcl | 150 | 32 |
| Lactulose | Lactulose | 141 | 30 |
| Olanzapine | Olanzapine | 139 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 135 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 135 | 37 |
| Simvastatin | Simvastatin | 124 | 30 |
| Baclofen | Baclofen | 123 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 118 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 115 | 31 |
| Memantine Hcl | Memantine Hcl | 112 | 22 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 111 | 18 |
| Januvia | Sitagliptin Phosphate | 111 | 17 |
| Entresto | Sacubitril/Valsartan | 110 | 14 |
| Buspirone Hcl | Buspirone Hcl | 108 | 17 |
| Donepezil Hcl | Donepezil Hcl | 108 | 21 |
| Latanoprost | Latanoprost | 103 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 99 | 46 |
| Celecoxib | Celecoxib | 98 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 24 |
| Valsartan | Valsartan | 92 | 18 |
| Montelukast Sodium | Montelukast Sodium | 84 | 14 |
| Benazepril Hcl | Benazepril Hcl | 82 | 17 |
| Tramadol Hcl | Tramadol Hcl | 82 | 19 |
| Allopurinol | Allopurinol | 80 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 78 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 78 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 35 |
| Ketoconazole | Ketoconazole | 77 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 76 | 38 |
| Amiodarone Hcl | Amiodarone Hcl | 71 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 22 |
| Glipizide | Glipizide | 65 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | suppressed |
| Lorazepam | Lorazepam | 62 | 22 |
| Midodrine Hcl | Midodrine Hcl | 59 | 20 |
| Humulin R | Insulin Regular, Human | 56 | 16 |
| Kerendia | Finerenone | 56 | suppressed |
| Ozempic | Semaglutide | 56 | suppressed |
| Digoxin | Digoxin | 54 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 54 | suppressed |
| Tradjenta | Linagliptin | 54 | suppressed |
| Atenolol | Atenolol | 53 | suppressed |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 50 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | 17 |
| Santyl | Collagenase Clostridium Hist. | 48 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 12 |
| Spironolactone | Spironolactone | 45 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 44 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 43 | suppressed |
| Prednisone | Prednisone | 42 | 19 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 22 |
| Sevelamer Carbonate | Sevelamer Carbonate | 36 | suppressed |
| Ezetimibe | Ezetimibe | 35 | 12 |
| Haloperidol | Haloperidol | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 34 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 27 |
| Sertraline Hcl | Sertraline Hcl | 33 | suppressed |
| Levemir Flexpen | Insulin Detemir | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Azithromycin | Azithromycin | 31 | 28 |
| Sodium Chloride | 0.9 % Sodium Chloride | 31 | 16 |
| Lacosamide | Lacosamide | 29 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 20 |
| Glyburide | Glyburide | 25 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 22 |
| Dorzolamide Hcl | Dorzolamide Hcl | 24 | suppressed |
| Ritonavir | Ritonavir | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 22 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Calcium Acetate | Calcium Acetate | 21 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | 11 |
| Nystatin | Nystatin | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 11 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Valproic Acid | Valproic Acid | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 14 | suppressed |
| Hydroxyurea | Hydroxyurea | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Prezista | Darunavir | 12 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Alogliptin | Alogliptin Benzoate | 11 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $360.31 · 12 records | ANI Pharmaceuticals, Inc. | AFREZZA, AIRSUPRA, CAPLYTA, COBENFY, Kerendia, NEXLETOL, PURIFIED CORTROPHIN GEL, REXULTI, XIFAXAN, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error